Synthesis, anticonvulsant screening, and molecular modeling studies of new arylalkylimidazole oxime ether derivatives

Basit Öğe Kaydı
dc.authoridOzdemir, Zenyep/0000-0003-4559-2305
dc.authoridSARI, SUAT/0000-0002-8248-4218
dc.authoridSARI, SUAT/0000-0002-8248-4218
dc.authoridKarakurt, Arzu/0000-0003-2209-0871
dc.authorwosidOzdemir, Zenyep/AAJ-6384-2020
dc.authorwosidSARI, SUAT/JCD-8070-2023
dc.authorwosidSARI, SUAT/A-5249-2017
dc.authorwosidKarakurt, Arzu/ABH-9340-2020
dc.contributor.authorOzdemir, Zeynep
dc.contributor.authorSari, Suat
dc.contributor.authorKarakurt, Arzu
dc.contributor.authorDalkara, Sevim
dc.date.accessioned2024-08-04T20:45:33Z
dc.date.available2024-08-04T20:45:33Z
dc.date.issued2019
dc.departmentİnönü Üniversitesien_US
dc.description.abstractIn this study, 15 new oxime ether derivatives were synthesized and their anticonvulsant activities were screened in vivo. The compounds were synthesized by the reaction of various alkyl halides with 1-(2-naphthyl)-2-(1H-imidazol-1-yl)ethanone oxime. Their anticonvulsant activities were determined using acute (maximal electroshock, subcutaneous metrazol [SCM], and 6 Hz seizure test) and chronic (corneal-kindled mouse) seizure models, their neurotoxic effects were evaluated by models of behavioral toxicity according to the Epilepsy Therapy Screening Program protocol of the NIH. All our compounds were protective in at least one of the tests. Quantification studies were applied to some of the active compounds and the intraperitoneal ED50 values in mice were found between 25.48 and 99.56 mg/kg. Some pharmacokinetic properties of the compounds were predicted in silico and molecular docking studies were performed to provide insights into their possible anticonvulsant mechanism regarding their SCM activity.en_US
dc.description.sponsorshipScientific and Technological Research Council of Turkey [110S270]en_US
dc.description.sponsorshipScientific and Technological Research Council of Turkey, Grant/Award Number: 110S270en_US
dc.identifier.doi10.1002/ddr.21491
dc.identifier.endpage280en_US
dc.identifier.issn0272-4391
dc.identifier.issn1098-2299
dc.identifier.issue2en_US
dc.identifier.pmid30474215en_US
dc.identifier.scopus2-s2.0-85057470740en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.startpage269en_US
dc.identifier.urihttps://doi.org/10.1002/ddr.21491
dc.identifier.urihttps://hdl.handle.net/11616/98551
dc.identifier.volume80en_US
dc.identifier.wosWOS:000466422300009en_US
dc.identifier.wosqualityQ3en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherWileyen_US
dc.relation.ispartofDrug Development Researchen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectanticonvulsanten_US
dc.subject(Arylalkyl)azoleen_US
dc.subjectimidazoleen_US
dc.subjectnafimidoneen_US
dc.subjectoxime etheren_US
dc.titleSynthesis, anticonvulsant screening, and molecular modeling studies of new arylalkylimidazole oxime ether derivativesen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu